# An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

> **NCT00200447** · PHASE2 · COMPLETED · sponsor: **Molecular NeuroImaging** · enrollment: 3 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** carbidopa/l-dopa
- **DRUG:** carbidopa/l-dopa/entacapone
- **DRUG:** Stalevo
- **PROCEDURE:** [123I]-IBZM imaging

## Key facts

- **NCT ID:** NCT00200447
- **Lead sponsor:** Molecular NeuroImaging
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2008-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00200447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00200447, "An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00200447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*